CN107260695A - 硝唑尼特的控制释放药物剂型 - Google Patents

硝唑尼特的控制释放药物剂型 Download PDF

Info

Publication number
CN107260695A
CN107260695A CN201710263825.6A CN201710263825A CN107260695A CN 107260695 A CN107260695 A CN 107260695A CN 201710263825 A CN201710263825 A CN 201710263825A CN 107260695 A CN107260695 A CN 107260695A
Authority
CN
China
Prior art keywords
nitazoxanide
amount
analog
dosage form
layer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201710263825.6A
Other languages
English (en)
Chinese (zh)
Inventor
珍·弗朗索瓦·罗西诺尔
马克·艾尔斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Romark Laboratories LC
Original Assignee
Romark Laboratories LC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Romark Laboratories LC filed Critical Romark Laboratories LC
Publication of CN107260695A publication Critical patent/CN107260695A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
CN201710263825.6A 2009-02-13 2010-02-12 硝唑尼特的控制释放药物剂型 Pending CN107260695A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20228509P 2009-02-13 2009-02-13
US61/202,285 2009-02-13
CN2010800164251A CN102395276A (zh) 2009-02-13 2010-02-12 硝唑尼特的控制释放药物剂型

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN2010800164251A Division CN102395276A (zh) 2009-02-13 2010-02-12 硝唑尼特的控制释放药物剂型

Publications (1)

Publication Number Publication Date
CN107260695A true CN107260695A (zh) 2017-10-20

Family

ID=42560126

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201710263825.6A Pending CN107260695A (zh) 2009-02-13 2010-02-12 硝唑尼特的控制释放药物剂型
CN2010800164251A Pending CN102395276A (zh) 2009-02-13 2010-02-12 硝唑尼特的控制释放药物剂型

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN2010800164251A Pending CN102395276A (zh) 2009-02-13 2010-02-12 硝唑尼特的控制释放药物剂型

Country Status (23)

Country Link
US (5) US8524278B2 (cg-RX-API-DMAC10.html)
EP (1) EP2395840B1 (cg-RX-API-DMAC10.html)
JP (3) JP5726766B2 (cg-RX-API-DMAC10.html)
KR (1) KR101697800B1 (cg-RX-API-DMAC10.html)
CN (2) CN107260695A (cg-RX-API-DMAC10.html)
AU (3) AU2010213678B2 (cg-RX-API-DMAC10.html)
BR (1) BRPI1007945C8 (cg-RX-API-DMAC10.html)
CA (1) CA2752233C (cg-RX-API-DMAC10.html)
CO (1) CO6501159A2 (cg-RX-API-DMAC10.html)
CY (1) CY1123162T1 (cg-RX-API-DMAC10.html)
DK (1) DK2395840T3 (cg-RX-API-DMAC10.html)
EA (1) EA029018B1 (cg-RX-API-DMAC10.html)
ES (1) ES2797493T3 (cg-RX-API-DMAC10.html)
HR (1) HRP20201055T1 (cg-RX-API-DMAC10.html)
HU (1) HUE049501T2 (cg-RX-API-DMAC10.html)
IL (1) IL214624A0 (cg-RX-API-DMAC10.html)
LT (1) LT2395840T (cg-RX-API-DMAC10.html)
MX (2) MX381895B (cg-RX-API-DMAC10.html)
PL (1) PL2395840T3 (cg-RX-API-DMAC10.html)
PT (1) PT2395840T (cg-RX-API-DMAC10.html)
SI (1) SI2395840T1 (cg-RX-API-DMAC10.html)
UA (1) UA107564C2 (cg-RX-API-DMAC10.html)
WO (1) WO2010093854A1 (cg-RX-API-DMAC10.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110025621A (zh) * 2019-03-13 2019-07-19 中国农业科学院上海兽医研究所(中国动物卫生与流行病学中心上海分中心) 替唑尼特和硝唑尼特在制备抗炎药物中的应用

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2008008723A (es) * 2006-01-09 2008-09-26 Romark Lab Lc Tratamiento de la hepatitis viral.
MX381895B (es) 2009-02-13 2025-03-13 Romark Laboratories Lc Formulaciones farmaceuticas de liberacion controlada de nitazoxanida.
US9498441B2 (en) 2012-01-27 2016-11-22 Siegfried Rhein S.A. De C.V. Nitazoxadine composition and process to prepare same
US20150017242A1 (en) * 2012-02-20 2015-01-15 Lupin Limited Bilayer Tablet of Dronedarone
KR101639692B1 (ko) * 2013-12-13 2016-07-14 제일약품주식회사 2 이상의 유효성분을 포함하는 구강 내 속붕해 다중유닛 약제학적 조성물
JP6633092B2 (ja) 2014-11-11 2020-01-22 ロマーク ラボラトリーズ，リミティド カンパニー チゾキサニド、その類似体又は塩のプロドラッグを用いる組成物及び治療方法
HK1250945A1 (zh) 2016-03-31 2019-01-18 罗马克实验室有限公司 用於治疗病毒性感染的噻唑化物化合物
IL262186B2 (en) * 2016-04-11 2023-10-01 Genfit Synergistic combinations of nitazoxanide (ntz) compounds and statins
US10905680B2 (en) * 2016-04-11 2021-02-02 Genfit Methods of treatment for cholestatic and fibrotic diseases
AU2018231044B2 (en) * 2017-03-08 2023-04-06 Cinrx Pharma, Llc Pharmaceutical formulations of phloroglucinol and trimethylphloroglucinol
SG11201907673YA (en) * 2017-03-13 2019-09-27 Genfit Pharmaceutical compositions for combination therapy
US11173149B2 (en) 2017-04-18 2021-11-16 Romark Laboratories L.C. Inhibition of protein disulfide-isomerase A3
EP3639854B1 (en) 2017-06-16 2026-01-07 The Doshisha Mtor-inhibitor-containing medicine for treating or preventing fuchs' endothelial corneal dystrophy
WO2018230713A1 (ja) * 2017-06-16 2018-12-20 学校法人同志社 カスパーゼ阻害活性を有する化合物、これらの化合物を含む、角膜内皮の症状、障害または疾患を治療または予防するための医薬およびその応用
CN108524460B (zh) * 2018-05-14 2021-01-01 佛山市南海东方澳龙制药有限公司 烯啶虫胺双层片
WO2019241376A1 (en) 2018-06-14 2019-12-19 The Trustees Of Columbia University In The City Of New York Treatment of cognitive disorders using nitazoxanide (ntz), nitazoxanide (ntz) analogs, and metabolites thereof
CN111012788B (zh) * 2019-12-12 2021-01-15 武汉职业技术学院 硝唑尼特和替唑尼特在制备抗猪繁殖与呼吸综合征病毒药物中的应用
US20230040902A1 (en) * 2019-12-19 2023-02-09 Celltrion Inc. Pharmaceutical Formulation Comprising Cibenzoline or Salt Thereof
JP2023537237A (ja) 2020-07-20 2023-08-31 ロマーク ラボラトリーズ，リミティド カンパニー チゾキサニドおよび２－ヒドロキシ－ｎ－（５－クロロ－１，３－チアゾル－２－イル）ベンズアミド（ｒｍ－４８４８）とエタノールアミン、モルホリン、プロパノールアミン、ピペラジン、およびｎ－メチルピペラジンの結晶塩
IL300801A (en) 2020-08-24 2023-04-01 Romark Laboratories Lc Use of thiazolides against the corona virus
WO2022130406A1 (en) * 2020-12-15 2022-06-23 Cipla Limited Inhalation composition of nitazoxanide or its derivatives for use in coronavirus disease
US20240417381A1 (en) 2021-10-05 2024-12-19 Council Of Scientific And Industrial Research An Indian Registered Body Incorporated An improved process for the preparation of nitazoxanide and intermediates thereof
CN114259492A (zh) * 2021-12-21 2022-04-01 中以海德人工智能药物研发股份有限公司 硝唑尼特在治疗乙肝中的应用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1255060A (zh) * 1997-05-07 2000-05-31 罗马克实验室有限公司 脱乙酰基硝噻醋柳胺和硝噻醋柳胺的药用组合物
CN1426298A (zh) * 2000-04-19 2003-06-25 史密丝克莱恩比彻姆有限公司 组合物
CN1438889A (zh) * 2000-06-26 2003-08-27 拜尔公司 喹诺酮类抗生素的缓释制剂及其制备方法
US20060141037A1 (en) * 2004-12-29 2006-06-29 J. B. Chemicals & Pharmaceuticals Ltd. Bilayer tablets of oxcarbazepine for controlled delivery and a process of preparation thereof
US20070167504A1 (en) * 2006-01-09 2007-07-19 Jean-Francois Rossignol Viral hepatitis treatment
US20080299188A1 (en) * 2007-05-14 2008-12-04 Pfizer Inc. Controlled release dosage forms combining immediate release and sustainted release of low-solubility drug

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1437800A (en) 1973-08-08 1976-06-03 Phavic Sprl Derivatives of 2-benzamido-5-nitro-thiazoles
JPH06316517A (ja) * 1993-02-22 1994-11-15 Grelan Pharmaceut Co Ltd 放出制御製剤
US5578621A (en) 1994-09-08 1996-11-26 Romark Lab Lc Benzamide derivatives
US5387598A (en) 1994-04-13 1995-02-07 Rossignol; Jean-Francois Composition and galenic formulation suitable for combatting affections of the lower abdomen
US5968961A (en) 1997-05-07 1999-10-19 Romark Laboratories, L.C. Pharmaceutical compositions of tizoxanide and nitazoxanide
MX9604483A (es) 1994-09-08 1998-02-28 Jean-Francois Rossignol Derivados de benzamida, composiciones que contienen dicho derivado y uso de las mismas.
US5948440A (en) 1997-12-17 1999-09-07 Ranbaxy Laboratories Limited Modified release matrix formulation of cefaclor and cephalexin
IL142896A0 (en) 1998-11-02 2002-04-21 Elan Corp Plc Multiparticulate modified release composition
JP4637338B2 (ja) * 2000-09-22 2011-02-23 大塚製薬株式会社 シロスタゾール有核錠
CA2426666A1 (en) 2000-09-29 2002-04-04 Solvay Pharmaceuticals B.V. Ion-strength independent sustained release pharmaceutical formulation
US7074417B2 (en) 2000-10-13 2006-07-11 Advancis Pharmaceutical Corporation Multiple-delayed release anti-viral product, use and formulation thereof
MXPA04002973A (es) 2001-09-28 2005-06-20 Johnson & Johnson Formas de dosis de liberacion modificada.
KR20040044992A (ko) 2001-09-28 2004-05-31 썬 파마슈티컬 인더스트리스 리미티드 당뇨병 치료용 투여형태
US7985422B2 (en) * 2002-08-05 2011-07-26 Torrent Pharmaceuticals Limited Dosage form
AR045330A1 (es) 2003-08-07 2005-10-26 Sb Pharmco Inc Forma de dosificacion oral, procedimiento para su preparacion y uso del compuesto 5-(4-(2-(n-metil-n- (2-piridil)amino)etoxi )bencil) tiazolidin-2,4-diona o una sal o solvato farmaceuticamente aceptable del mismo para prepararla
GB0319874D0 (en) * 2003-08-22 2003-09-24 Glaxo Group Ltd Novel formulation
UA90864C2 (en) 2004-09-09 2010-06-10 Ромарк Лебораториз, Л.К. Halogenated benzamide derivatives
AU2006235490A1 (en) 2005-04-12 2006-10-19 Romark Laboratories, L.C. Methods for treating diseases through the function of molecular chaperones such as protein disulfide isomerases, pharmaceutical compositions comprising them, and screening methods for identifying therapeutic agents
FR2889811B1 (fr) 2005-08-19 2009-10-09 Sanofi Aventis Sa Association d'un agent hypnotique a duree d'action longue et d'un agent hypnotique a duree d'action courte, composition pharmaceutique la contenant et son application en therapeutique.
JP2006335771A (ja) * 2006-09-22 2006-12-14 Takeda Chem Ind Ltd 徐放性製剤およびその製造方法
US20080286344A1 (en) * 2007-05-16 2008-11-20 Olivia Darmuzey Solid form
EP2178852B9 (en) 2007-08-03 2016-06-22 Romark Laboratories, L.C. Alkylsulfonyl-substituted thiazolide compounds
MX381895B (es) * 2009-02-13 2025-03-13 Romark Laboratories Lc Formulaciones farmaceuticas de liberacion controlada de nitazoxanida.

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1255060A (zh) * 1997-05-07 2000-05-31 罗马克实验室有限公司 脱乙酰基硝噻醋柳胺和硝噻醋柳胺的药用组合物
CN1426298A (zh) * 2000-04-19 2003-06-25 史密丝克莱恩比彻姆有限公司 组合物
CN1438889A (zh) * 2000-06-26 2003-08-27 拜尔公司 喹诺酮类抗生素的缓释制剂及其制备方法
US20060141037A1 (en) * 2004-12-29 2006-06-29 J. B. Chemicals & Pharmaceuticals Ltd. Bilayer tablets of oxcarbazepine for controlled delivery and a process of preparation thereof
US20070167504A1 (en) * 2006-01-09 2007-07-19 Jean-Francois Rossignol Viral hepatitis treatment
US20080299188A1 (en) * 2007-05-14 2008-12-04 Pfizer Inc. Controlled release dosage forms combining immediate release and sustainted release of low-solubility drug

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
张光杰等: "《药用辅料应用技术》", 31 December 1991, 中国医药科技出版社 *
李乃胜: "《当代科学技术发展前沿》", 3 June 2004, 中国海洋大学出版社 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110025621A (zh) * 2019-03-13 2019-07-19 中国农业科学院上海兽医研究所(中国动物卫生与流行病学中心上海分中心) 替唑尼特和硝唑尼特在制备抗炎药物中的应用

Also Published As

Publication number Publication date
US20160243087A1 (en) 2016-08-25
JP6117845B2 (ja) 2017-04-19
KR101697800B1 (ko) 2017-01-18
CA2752233C (en) 2017-01-03
EA201190127A1 (ru) 2012-03-30
EP2395840B1 (en) 2020-04-15
BRPI1007945B1 (pt) 2020-08-04
MX348282B (es) 2017-06-05
US20190321338A1 (en) 2019-10-24
AU2017203148A1 (en) 2017-06-01
IL214624A0 (en) 2011-09-27
BRPI1007945A2 (pt) 2015-09-01
BRPI1007945C1 (pt) 2020-09-01
HUE049501T2 (hu) 2020-09-28
CA2752233A1 (en) 2010-08-19
SI2395840T1 (sl) 2020-08-31
US11426388B2 (en) 2022-08-30
US20100209505A1 (en) 2010-08-19
PL2395840T3 (pl) 2020-09-07
BRPI1007945C8 (pt) 2021-05-25
CO6501159A2 (es) 2012-08-15
EA029018B1 (ru) 2018-01-31
JP5726766B2 (ja) 2015-06-03
EP2395840A4 (en) 2013-12-25
JP6491174B2 (ja) 2019-03-27
US20180085353A1 (en) 2018-03-29
JP2012518002A (ja) 2012-08-09
JP2015143258A (ja) 2015-08-06
US9827227B2 (en) 2017-11-28
LT2395840T (lt) 2020-07-10
DK2395840T3 (da) 2020-06-08
EP2395840A1 (en) 2011-12-21
CY1123162T1 (el) 2021-10-29
AU2010213678B2 (en) 2015-11-26
MX2011008530A (es) 2011-10-14
US20140065215A1 (en) 2014-03-06
WO2010093854A1 (en) 2010-08-19
UA107564C2 (uk) 2015-01-26
ES2797493T3 (es) 2020-12-02
PT2395840T (pt) 2020-07-06
BRPI1007945B8 (pt) 2020-08-18
HRP20201055T1 (hr) 2020-10-30
MX381895B (es) 2025-03-13
CN102395276A (zh) 2012-03-28
US10383855B2 (en) 2019-08-20
AU2016200971A1 (en) 2016-03-03
JP2017061561A (ja) 2017-03-30
KR20120008024A (ko) 2012-01-25
US8524278B2 (en) 2013-09-03
AU2017203148B2 (en) 2018-08-09
US9351937B2 (en) 2016-05-31
AU2016200971B2 (en) 2017-02-23
AU2010213678A1 (en) 2011-09-01

Similar Documents

Publication Publication Date Title
US11426388B2 (en) Controlled release pharmaceutical formulations of nitazoxanide
EP2341910B1 (en) Immediate release dosage forms of sodium oxybate
EP2533767A1 (en) Pharmaceutical compositions comprising a combination of metformin and sitagliptin
ES2286716T3 (es) Composicion farmaceutica de liberacion controlada y proceso para preparar la misma.
WO2020089761A1 (en) Pharmaceutical composition comprising of remogliflozin or salt or ester thereof and vildagliptin or salt thereof
US20260069569A1 (en) Ebselen containing oral dosage forms
HK1165217B (en) Controlled release pharmaceutical formulations of nitazoxanide
HK1165217A (en) Controlled release pharmaceutical formulations of nitazoxanide
WO2021053564A1 (en) Pharmaceutical composition comprising remogliflozin or salt or ester thereof and teneligliptin or salt thereof
RU2020143156A (ru) Фармацевтическая комбинация, композиция и комбинированный состав, содержащий активатор глюкокиназы и бигуанидное гипогликемическое лекарственное средство, а также способ их приготовления и их применение

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20171020